Atorvastatin (ATV)-Loaded Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhance the Therapeutic Efficacy of Acute Kidney Injury

Recent Advances in Nanomaterials for the Treatment of Acute Kidney Injury

Acute kidney injury (AKI) is a serious clinical syndrome with high morbidity, elevated mortality, and poor prognosis, commonly considered a "sword of Damocles" for hospitalized patients, especially those in intensive care units. Oxidative stress, inflammation, and apoptosis, caused by the excessive production of reactive oxygen species (ROS), play a key role in AKI progression. Hence, the investigation of effective and safe antioxidants and inflammatory regulators to scavenge overexpressed ROS and regulate excessive inflammation has become a promising therapeutic option. However, the unique physiological structure and complex pathological alterations in the kidneys render traditional therapies ineffective, impeding the residence and efficacy of most antioxidant and anti-inflammatory small molecule drugs within the renal milieu. Recently, nanotherapeutic interventions have emerged as a promising and prospective strategy for AKI, overcoming traditional treatment dilemmas through alterations in size, shape, charge, and surface modifications. This Review succinctly summarizes the latest advancements in nanotherapeutic approaches for AKI, encompassing nanozymes, ROS scavenger nanomaterials, MSC-EVs, and nanomaterials loaded with antioxidants and inflammatory regulator. Following this, strategies aimed at enhancing biocompatibility and kidney targeting are introduced. Furthermore, a brief discussion on the current challenges and future prospects in this research field is presented, providing a comprehensive overview of the evolving landscape of nanotherapeutic interventions for AKI.

Multifunctional mesoporous silica nanoparticles for biomedical applications

Mesoporous silica nanoparticles (MSNs) are recognized as a prime example of nanotechnology applied in the biomedical field, due to their easily tunable structure and composition, diverse surface functionalization properties, and excellent biocompatibility. Over the past two decades, researchers have developed a wide variety of MSNs-based nanoplatforms through careful design and controlled preparation techniques, demonstrating their adaptability to various biomedical application scenarios. With the continuous breakthroughs of MSNs in the fields of biosensing, disease diagnosis and treatment, tissue engineering, etc., MSNs are gradually moving from basic research to clinical trials. In this review, we provide a detailed summary of MSNs in the biomedical field, beginning with a comprehensive overview of their development history. We then discuss the types of MSNs-based nanostructured architectures, as well as the classification of MSNs-based nanocomposites according to the elements existed in various inorganic functional components. Subsequently, we summarize the primary purposes of surface-functionalized modifications of MSNs. In the following, we discuss the biomedical applications of MSNs, and highlight the MSNs-based targeted therapeutic modalities currently developed. Given the importance of clinical translation, we also summarize the progress of MSNs in clinical trials. Finally, we take a perspective on the future direction and remaining challenges of MSNs in the biomedical field.

Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney

Currently, there are no clinical drugs available to treat acute kidney injury (AKI). Given the high prevalence and high mortality rate of AKI, the development of drugs to effectively treat AKI is a huge unmet medical need and a research hotspot. Although existing evidence fully demonstrates that reactive oxygen and nitrogen species (RONS) burst at the AKI site is a major contributor to AKI progression, the heterogeneity, complexity, and unique physiological structure of the kidney make most antioxidant and anti-inflammatory small molecule drugs ineffective because of the lack of kidney targeting and side effects. Recently, nanodrugs with intrinsic kidney targeting through the control of size, shape, and surface properties have opened exciting prospects for the treatment of AKI. Many antioxidant nanodrugs have emerged to address the limitations of current AKI treatments. In this review, we systematically summarized for the first time about the emerging nanodrugs that exploit the pathological and physiological features of the kidney to overcome the limitations of traditional small-molecule drugs to achieve high AKI efficacy. First, we analyzed the pathological structural characteristics of AKI and the main pathological mechanism of AKI: hypoxia, harmful substance accumulation-induced RONS burst at the renal site despite the multifactorial initiation and heterogeneity of AKI. Subsequently, we introduced the strategies used to improve renal targeting and reviewed advances of nanodrugs for AKI: nano-RONS-sacrificial agents, antioxidant nanozymes, and nanocarriers for antioxidants and anti-inflammatory drugs. These nanodrugs have demonstrated excellent therapeutic effects, such as greatly reducing oxidative stress damage, restoring renal function, and low side effects. Finally, we discussed the challenges and future directions for translating nanodrugs into clinical AKI treatment.

•

AKI is a common clinical acute syndrome with high morbidity and mortality but without effective clinical drug available.

•

Hypoxia and accumulation of toxic substances are key pathological features of various heterogeneous AKI.

•

Excessive RONS is the core of the pathological mechanism of AKI.

•

The development of nanodrugs is expected to achieve successful treatment in AKI.

Intra-Epidural Space Injection of OX26-PEGylated Selenium Nanoparticles Enhances Motor Function and Decrease the Risk of Neural Damage in Animal Model of Subarachnoid Hemorrhage

Objective: To evaluate the effectiveness of PEGylated (PEG) OX26 loaded with Selenium (Se) on locomotor activity and brain function and exploring underlying mechanism in animal model of subarachnoid hemorrhage (SAH). Methods: Thoracis spinal cord injury in Wistar rats was used to induce SAH and intra-epidural injection of OX26-PEG-Se nanoparticles (NPs) was then applied. Locomotor function test was used to evaluate the behavioral outcome in addition, ELISA kit was used to evaluate the serum level of NSE and S100B. Immunofluorescent imaging was used to detect the expression of eNOS and NT-1. In addition, NeuN staing was used to assess the neural damage. Results: The locomotor function of animals with SAH was significantly increase afgter treating with OX26-PEG-Se NPs. In addition, the expression levels of NSE and S100B were significantly decrease after treating animals with OX26-PEG-Se NPs in comparison to sham operated animals. We observed that OX26-PEG-Se NPs decrease the neural damage and the level of NT-1, while increase the eNOS in brain. Conclusion: Intra-epidural injection of OX26-PEG-Se NPs improved the locomotor activity and also inhibit the risk of neural damage through ET-1/eNOS pathway after subarachnoid hemorrhage.

Mitochondria-Targeting-Based of Paclitaxel-Loaded Triphenylphosphine-Pluronic F127-Hyaluronic Acid Nanomicelles in Multi-Drug Resistant Hepatocellular Carcinoma

Background: In this study a new novel nanomicelle (TPH) sco-loaded with triphenylphosphine (TPP)-Pluronic F127-hyaluronic acid (HA) and Paclitaxel (PTX) has been designed to treat multidrug resistant hepatocellular carcinoma (HCC). Methods: TPH was initially synthesized by ester bond formation with mitochondria-targeting TPP agent and TPH nanomicelles loaded with PTX (TPH/PTX) had outstanding physical characteristics in human multi drug-resistant HCC cell line Bel7402/5-FU. Cytotoxicity and hemocompatibility assessments, nanomicelle cellular absorption and mitochondrial targeting, and in vivo xenograft imaging was used to evaluate that the nonemicells delivered into target cell and components. Results: The results of fluorescence test showed that TPP could promote the fusion of nanomicells to human multi drugresistant HCC cell line Bel7402/5-FU, and targeted the mitochondria, and also improved the targeting and retention of drugs in liver tumors. The results of cell efficacy showed that TPH/PTX induced a strong apoptosis effect, which could significantly reduce the mitochondrial membrane Zeta potential, increase the level of intracellular ROS and the release of Caspase-3, significantly enhanced the pro-apoptotic protein (Bcl-2), decrease the expression level of anti-apoptotic protein (Bax). Conclusion: TPH/PTX has a promising mitochondrial targeting function, and can enhance the effect of drugs on promoting apoptosis of drug resistant HCC cells.

Construction of calcium carbonate-liposome dual-film coated mesoporous silica as a delayed drug release system for antitumor therapy

As is well known to all, delivering drug precisely to the tumor site is beneficial to improve antitumor effect. In this study, we reported mesoporous silica nanoparticles (MSNs) coated with dual-film of calcium carbonate (CaCO₃) and lipid bilayer (denoted as MSNs@CaCO₃@liposomes) innovatively which achieve sustained drug release anchored at tumor microenvironment and enhanced biocompatibility. The pH-sensitive CaCO₃ film acted as a guide to cap the pore channels of MSNs allowed pH-triggered drug release when transporting into cancer cells. Furthermore, MSNs@CaCO₃ was capsuled by lipid bilayer to improve cellular uptake efficiency and biocompatibility in blood circulation. Morphology of nanoparticles was characterized by transmission electron microscopy (TEM) and field emission scanning electron microscopy (FESEM) to confirm that double films were coated successfully. Doxorubicin hydrochloride (DOX) was efficaciously loaded into mesoporous pores as a model drug with a high drug loading content of 28%, forming DOX-loaded MSNs@CaCO₃@liposomes (DOX/MSNs@CaCO₃@liposomes). Non-specific protein adsorption and hemolysis test revealed enhanced biocompatibility. Drug release study in vitro showed DOX/MSNs@CaCO₃@liposomes could delay to release DOX at pH 5.0 and avoid releasing at pH 7.4. In vitro and in vivo antitumor efficiency evaluation showed that DOX/MSNs@CaCO₃@liposomes have a desirable inhibitory activity on tumor growth. Therefore, dual-film coated MSNs could be a good candidate for an antitumor drug delivery system.